- Trial Phase
- Phase 2 completed; Phase 2b/3 registrational program planned but not yet initiated
- Time to Market
- At least 3-5 years. Phase 2b/3 registrational program has FDA alignment but has not begun enrollment. Even with Fast Track designation, a full Phase 3 program, data analysis, and NDA submission typically takes multiple years.
- Why 4/10
- No imminent PDUFA date or pivotal readout scheduled within ~12 months. Phase 2 MINDFuL trial is completed and published (May 2026). The next catalyst is the planned integrated Phase 2b/3 registrational program which has FDA alignment but has not yet started enrollment. Near-term data presentations (AAIC July 12-15, 2026) are supportive but non-binary. XPro1595 is INMB's lead asset, but the defining binary catalyst is likely 12+ months away, capping impactScore at 4.
Watch for AAIC 2026 (July 12-15) imaging data and the eventual Phase 2b/3 protocol submission and first patient dosed. INMB has ~$21.4M cash (through Q1 2027) but the Phase 2b/3 program will likely require additional capital, creating dilution risk. The stock trades near its 52-week low (~$1.72) with a ~$43M market cap, reflecting the primary endpoint miss and cash concerns. Analyst consensus is Strong Buy with mean PT of $7.00, but this represents expectation of a successful registrational path, which is far from guaranteed.
Price Chart
Executive Summary
XPro1595 (pegipanermin) is INmune Bio's lead drug candidate — a first-in-class selective soluble TNF inhibitor targeting neuroinflammation in early Alzheimer's disease. The Phase 2 MINDFuL trial (n=207) missed its primary cognitive endpoint in the overall population but showed encouraging trends in a biomarker-enriched subgroup (amyloid-positive with 2+ inflammation markers). The FDA granted Fast Track designation (May 2026) and aligned on a Phase 2b/3 registrational pathway (Feb 2026). The stock trades at ~$1.72 (~$43M market cap) near its 52-week low, reflecting the mixed Phase 2 results, cash runway concerns (~$21.4M through Q1 2027), and the capital-intensive Phase 3 path ahead. The amyloid-targeting competition (Leqembi, Kisunla) is already approved, but XPro1595's novel anti-inflammatory mechanism could differentiate it if the registrational program succeeds.
How It Works
XPro1595 is a biologic drug (a modified protein) that selectively neutralizes only the soluble form of tumor necrosis factor (TNF), an inflammatory signaling molecule. Unlike older TNF-blocking drugs (like Humira or Enbrel) that block all TNF activity, XPro1595 preserves the beneficial immune functions of membrane-bound TNF while reducing harmful inflammation. It acts as a "dominant-negative" — it binds to soluble TNF and forms inactive complexes, preventing it from attaching to cell receptors and triggering inflammation. This is designed to treat Alzheimer's disease by reducing the chronic neuroinflammation that is thought to drive neurodegeneration.
Trial Status
Phase 2 MINDFuL trial (NCT05318976) is complete with 207 patients enrolled and results published in NPJ Dementia (May 2026). The primary cognitive endpoint (EMACC) was not met in the overall mITT population (n=200). However, in a pre-specified enriched subpopulation of amyloid-positive patients with 2+ inflammation biomarkers (n=100), consistent positive trends were observed. FDA granted Fast Track designation (May 2026) and aligned on an integrated Phase 2b/3 seamless adaptive registrational pathway (Feb 2026 End-of-Phase 2 meeting). An open-label extension study (NCT05522387) was terminated early with only 11 patients enrolled. New MRI imaging data (chi-separation analysis) showing statistically significant white matter myelin improvements (p<0.01) will be presented at AAIC July 12-15, 2026.
The Two-Sided Case
Upcoming Catalysts
- AAIC 2026 (July 12-15, London): Presentation of full chi-separation MRI imaging dataset showing white matter myelin and cortical microstructure results from Phase 2 MINDFuL trial
- Phase 2b/3 protocol submission to FDA and eventual first patient dosed — no specific date announced
- Potential partnership or licensing discussions (management mentioned global partnership plans in Feb 2026 webinar)
- Q2 2026 earnings report (estimated late July/August 2026) — cash position update
- CORDStrom UK MAA submission (separate pipeline asset) for conditional marketing authorization in RDEB — planned for 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
INmune Bio, Inc. Press Release INMB ·Originating report